Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 46Unknown 15Recruiting 10Not yet recruiting 8Active not recruiting 8Terminated 6Withdrawn 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1CNS 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × eribulin × Clear all
NCT03637868 2020-05-06

ERIBRAIN

Institut Paoli-Calmettes

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02215876 2016-04-15

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡